Myeloproliferative Neoplasms (MPNs) - Part 2: A Nursing Guide to Managing the Symptom Burden of MPNs

Overview

Journal Can Oncol Nurs J

Date 2019 Jun 1

PMID 31148831

Citations 3

Authors

Sabrina Fowlkes

Cindy Murray

Adrienne Fulford

Tammy De Gelder

Nancy Siddiq

Affiliations

Soon will be listed here.

Abstract

Myeloproliferative neoplasms (MPNs) are rare, yet potentially life-threatening, disorders caused by overproliferation of bone marrow stem cells. The symptom burden experienced by patients with the BCR-ABL1-negative MPNs (also referred to as the classical MPNs, i.e., essential thrombocythemia [ET], polycythemia vera [PV] and myelofibrosis [MF]) can be significant and can negatively impact quality of life (QOL). Since patients with these MPNs can live for several years, thereby requiring long-term treatment and follow-up, nurses play an essential role in communicating with these patients, assessing their symptoms, and educating them on treatments and self-management strategies that can reduce their symptom burden. This article, which is the second of a twopart series, was developed to provide nurses and other healthcare professionals with practical guidance for managing the symptom burden associated with the classical MPNs in order to help enhance their patients' overall health and QOL.

Citing Articles

Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies.

Carullo G, Rossi S, Giudice V, Pezzotta A, Chianese U, Scala P ACS Pharmacol Transl Sci. 2024; 7(7):2125-2142.

PMID: 39022363 PMC: 11249625. DOI: 10.1021/acsptsci.4c00208.

Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Dozzo A, Galvin A, Shin J, Scalia S, ODriscoll C, Ryan K Drug Deliv Transl Res. 2022; 13(8):2110-2141.

PMID: 35930221 PMC: 10315355. DOI: 10.1007/s13346-022-01189-4.

A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan.

Chang C, Chen C, Chiang I, Ku F, Lee Y, Siddiqui A J Patient Exp. 2021; 8:23743735211059053.

PMID: 34888413 PMC: 8649420. DOI: 10.1177/23743735211059053.

References

Mesa R, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S . The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2006; 109(1):68-76. DOI: 10.1002/cncr.22365. View

Saini K, Patnaik M, Tefferi A . Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010; 40(9):828-34. DOI: 10.1111/j.1365-2362.2010.02334.x. View

Neben-Wittich M, Brown P, Tefferi A . Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am J Hematol. 2010; 85(10):808-10. DOI: 10.1002/ajh.21819. View

Scherber R, Dueck A, Johansson P, Barbui T, Barosi G, Vannucchi A . The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011; 118(2):401-8. DOI: 10.1182/blood-2011-01-328955. View

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

Verstovsek S, Mesa R, Gotlib J, Levy R, Gupta V, Dipersio J . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807. PMC: 4822164. DOI: 10.1056/NEJMoa1110557. View

Cervantes F . How I treat splenomegaly in myelofibrosis. Blood Cancer J. 2012; 1(10):e37. PMC: 3255257. DOI: 10.1038/bcj.2011.36. View

Emanuel R, Dueck A, Geyer H, Kiladjian J, Slot S, Zweegman S . Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30(33):4098-103. PMC: 4872304. DOI: 10.1200/JCO.2012.42.3863. View

Mesa R, Gotlib J, Gupta V, Catalano J, Deininger M, Shields A . Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013; 31(10):1285-92. PMC: 4979167. DOI: 10.1200/JCO.2012.44.4489. View

10.

Mughal T, Vaddi K, Sarlis N, Verstovsek S . Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014; 7:89-101. PMC: 3912063. DOI: 10.2147/IJGM.S51800. View

11.

Vannucchi A, Kiladjian J, Griesshammer M, Masszi T, Durrant S, Passamonti F . Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5):426-35. PMC: 4358820. DOI: 10.1056/NEJMoa1409002. View

12.

Mesa R, Scherber R, Geyer H . Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015; 56(7):1989-99. DOI: 10.3109/10428194.2014.983098. View

13.

Hermouet S, Bigot-Corbel E, Gardie B . Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm. 2015; 2015:145293. PMC: 4619950. DOI: 10.1155/2015/145293. View

14.

Geyer H, Dueck A, Scherber R, Mesa R . Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators Inflamm. 2015; 2015:284706. PMC: 4619953. DOI: 10.1155/2015/284706. View

15.

Radia D, Geyer H . Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program. 2015; 2015:340-8. DOI: 10.1182/asheducation-2015.1.340. View

16.

Scherber R, Kosiorek H, Senyak Z, Dueck A, Clark M, Boxer M . Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2015; 122(3):477-85. DOI: 10.1002/cncr.29753. View

17.

Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S . Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016; 16:167. PMC: 4769833. DOI: 10.1186/s12885-016-2208-2. View

18.

Harrison C, Vannucchi A, Kiladjian J, Al-Ali H, Gisslinger H, Knoops L . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8):1701-7. PMC: 5399157. DOI: 10.1038/leu.2016.148. View